Tandem Diabetes Care - TNDM Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $75.50
Forecasted Upside: 71.86%
Number of Analysts: 9
Breakdown:
0 Sell Ratings
4 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$43.93 As of 02/7/2023 01:18 PM ET

▲ +0.66 (1.53%)

1 month | 3 months | 12 months

Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

^$75.50

▲ +71.86% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $75.50, with a high forecast of $130.00 and a low forecast of $43.00. The average price target represents a 71.86% upside from the last price of $43.93.

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/16/2021

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/14/2021

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/12/2022

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/13/2022

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

8/11/2022

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/9/2022

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/8/2023

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/7/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/26/2023	Wolfe Research	Initiated Coverage	Peer Perform		N/A
12/12/2022	Citigroup	Boost Target		$50.00 ➝ $55.00	Low
11/15/2022	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$43.00	Low
11/4/2022	Raymond James	Lower Target	Outperform	$92.00 ➝ $52.00	Low
11/3/2022	Cowen	Lower Target		$107.00 ➝ $61.00	Low
11/3/2022	Lake Street Capital	Lower Target		$150.00 ➝ $60.00	Low
11/3/2022	Craig Hallum	Lower Target		$105.00 ➝ $80.00	Low
11/3/2022	Cowen	Lower Target		$107.00 ➝ $61.00	Low
11/3/2022	Robert W. Baird	Lower Target		$76.00 ➝ $45.00	Low
11/3/2022	Piper Sandler	Lower Target	Overweight	$80.00 ➝ $70.00	Low
10/17/2022	Barclays	Initiated Coverage	Overweight	$75.00	Low
10/12/2022	Jefferies Financial Group	Initiated Coverage	Buy	$75.00	Low
10/5/2022	Citigroup	Lower Target		$98.00 ➝ $75.00	Low
8/9/2022	Robert W. Baird	Lower Target		$76.00	Low
8/9/2022	Wells Fargo & Company	Downgrade	Overweight ➝ Underweight	$82.00 ➝ $49.00	Low
8/4/2022	Lake Street Capital	Lower Target		$200.00 ➝ $150.00	Low
8/4/2022	Cowen	Lower Target		$141.00 ➝ $107.00	Low
8/4/2022	Piper Sandler	Lower Target	Overweight	$120.00 ➝ $80.00	N/A
8/4/2022	Wells Fargo & Company	Lower Target	Overweight	$166.00 ➝ $82.00	Low
8/4/2022	Raymond James	Lower Target	Outperform	$125.00 ➝ $90.00	Low
8/4/2022	Cowen	Lower Target		$141.00 ➝ $107.00	Low
8/4/2022	Citigroup	Lower Target		$107.00 ➝ $98.00	Low
5/17/2022	Citigroup	Lower Target		$155.00 ➝ $130.00	Medium
5/5/2022	Oppenheimer	Lower Target		$142.00 ➝ $130.00	High
5/5/2022	Piper Sandler	Lower Target		$170.00 ➝ $120.00	High
4/18/2022	SVB Leerink	Reiterated Rating	Market Perform		High
3/2/2022	Bank of America	Initiated Coverage	Neutral ➝ Neutral	$130.00	Low
2/23/2022	Wells Fargo & Company	Boost Target	Overweight	$160.00 ➝ $166.00	High
2/23/2022	Citigroup	Lower Target	Buy	$163.00 ➝ $155.00	High
2/23/2022	SVB Leerink	Lower Target	Market Perform	$140.00 ➝ $120.00	High
1/19/2022	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$137.00 ➝ $160.00	High
12/7/2021	Lake Street Capital	Boost Target	Buy	$165.00 ➝ $200.00	High
12/6/2021	Piper Sandler	Boost Target	Overweight	$140.00 ➝ $150.00	High
11/4/2021	Wells Fargo & Company	Boost Target	Equal Weight	$121.00 ➝ $137.00	High
11/4/2021	SVB Leerink	Boost Target	Market Perform	$135.00 ➝ $140.00	High
11/4/2021	Raymond James	Boost Target	Outperform	$120.00 ➝ $138.00	High
11/4/2021	Piper Sandler	Boost Target	Overweight	$132.00 ➝ $140.00	High
9/24/2021	SVB Leerink	Boost Target	Market Perform	$123.00 ➝ $135.00	Low
8/5/2021	SVB Leerink	Boost Target	Market Perform ➝ Market Perform	$102.00 ➝ $123.00	Low
8/5/2021	Oppenheimer	Boost Target	Outperform	$135.00 ➝ $140.00	Low
8/5/2021	Craig Hallum	Boost Target	Buy	$140.00 ➝ $153.00	High
8/5/2021	Wells Fargo & Company	Boost Target	Equal Weight	$112.00 ➝ $121.00	High
8/5/2021	Raymond James	Boost Target	Outperform	$115.00 ➝ $120.00	Medium
5/24/2021	Barclays	Initiated Coverage	Underweight	$90.00	Low
5/6/2021	Oppenheimer	Boost Target		$130.00 ➝ $135.00	Low
5/6/2021	SVB Leerink	Boost Target	Market Perform	$95.00 ➝ $102.00	High
4/1/2021	SVB Leerink	Lower Target	Market Perform	$115.00 ➝ $95.00	Low
3/31/2021	Oppenheimer	Reiterated Rating	Buy		High
2/25/2021	Lake Street Capital	Boost Target	Buy	$137.00 ➝ $150.00	High
12/15/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$105.00	High
11/6/2020	Raymond James	Boost Target	Outperform	$116.00 ➝ $124.00	High
11/6/2020	SVB Leerink	Boost Target	Market Perform	$120.00 ➝ $130.00	High
11/6/2020	Piper Sandler	Boost Target	Overweight	$125.00 ➝ $132.00	High
9/21/2020	Oppenheimer	Reiterated Rating	Buy	$120.00	High
8/28/2020	SVB Leerink	Boost Target	Market Perform	$115.00 ➝ $120.00	Low
8/20/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$120.00	High
7/31/2020	Raymond James	Boost Target	Outperform	$95.00 ➝ $116.00	Low
7/31/2020	Craig Hallum	Boost Target	Buy	$102.00 ➝ $140.00	High
7/31/2020	Lake Street Capital	Boost Target	Positive ➝ Buy	$125.00 ➝ $137.00	High
7/31/2020	SVB Leerink	Boost Target	Market Perform	$105.00 ➝ $115.00	High
7/31/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$130.00	High
7/31/2020	Piper Sandler	Boost Target	Overweight	$90.00 ➝ $125.00	High
7/7/2020	Cowen	Boost Target	Positive ➝ Outperform	$85.00 ➝ $110.00	Low
7/6/2020	Citigroup	Upgrade	Neutral ➝ Buy	$94.00 ➝ $120.00	Low
6/30/2020	Oppenheimer	Initiated Coverage	Buy	$102.00	Low
6/30/2020	Piper Sandler	Reiterated Rating	Buy	$90.00	Low
6/30/2020	Bank of America	Reiterated Rating	Hold	$100.00	Low
6/30/2020	Cowen	Reiterated Rating	Buy	$85.00	Low
6/22/2020	UBS Group	Boost Target	Buy	$98.00 ➝ $106.00	Low
6/22/2020	Oppenheimer	Boost Target	Reduce ➝ Outperform	$92.00 ➝ $102.00	Low
6/18/2020	Lake Street Capital	Boost Target		$100.00 ➝ $125.00	Low
6/18/2020	Raymond James	Boost Target	Outperform	$88.00 ➝ $95.00	Low
6/17/2020	Oppenheimer	Initiated Coverage	Buy	$92.00	Low
6/3/2020	Citigroup	Boost Target	Average ➝ Neutral	$81.00 ➝ $94.00	Low
5/22/2020	Bank of America	Boost Target	Neutral	$85.00 ➝ $95.00	Low
5/1/2020	UBS Group	Lower Target	Buy	$100.00 ➝ $98.00	High
5/1/2020	Citigroup	Boost Target	Neutral	$74.00 ➝ $81.00	High
5/1/2020	Stifel Nicolaus	Boost Target	Hold	$65.00 ➝ $75.00	Medium
5/1/2020	Oppenheimer	Reiterated Rating	Buy	$92.00	High
5/1/2020	SVB Leerink	Boost Target	Market Perform	$85.00 ➝ $88.00	High
4/27/2020	Raymond James	Lower Target	Outperform	$91.00 ➝ $81.00	Low
4/24/2020	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
4/20/2020	Craig Hallum	Lower Target	Buy	$108.00 ➝ $102.00	Medium
3/27/2020	Citigroup	Lower Target	Neutral	$89.00 ➝ $74.00	High
3/23/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High
3/4/2020	Citigroup	Initiated Coverage	Neutral	$89.00	Medium
2/25/2020	Oppenheimer	Boost Target		$84.00 ➝ $97.00	High
2/25/2020	Piper Sandler	Boost Target	Overweight	$70.00 ➝ $90.00	High
2/25/2020	Craig Hallum	Boost Target	Buy	$92.00 ➝ $108.00	High
2/25/2020	Stifel Nicolaus	Boost Target	Hold	$70.00 ➝ $77.00	High
2/25/2020	Raymond James	Boost Target	Outperform	$85.00 ➝ $91.00	High
2/25/2020	Cowen	Reiterated Rating	Outperform	$85.00 ➝ $90.00	High
2/13/2020	Cowen	Boost Target	Outperform	$70.00 ➝ $85.00	Medium
2/12/2020	Craig Hallum	Reiterated Rating	Buy	$92.00	High
2/5/2020	Raymond James	Initiated Coverage	Outperform	$85.00	Low
2/4/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$71.00 ➝ $75.00	Low
12/13/2019	Craig Hallum	Reiterated Rating	Buy	$92.00	Low
10/17/2019	Guggenheim	Initiated Coverage	Buy	$76.00	Low
10/4/2019	UBS Group	Upgrade	Neutral ➝ Buy	$75.00	Low
8/2/2019	Oppenheimer	Boost Target		$80.00 ➝ $84.00	Medium
6/17/2019	Lake Street Capital	Reiterated Rating	Buy		Medium
5/17/2019	Bank of America	Reiterated Rating	Neutral	$65.00	Medium
5/13/2019	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$83.00	Low
5/1/2019	Oppenheimer	Boost Target	Outperform	$68.00 ➝ $80.00	Medium
5/1/2019	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$58.00 ➝ $70.00	Medium
5/1/2019	Craig Hallum	Reiterated Rating	Buy	$70.00 ➝ $84.00	High
4/30/2019	UBS Group	Boost Target	Neutral ➝ Neutral	$53.00 ➝ $66.00	High
3/8/2019	BMO Capital Markets	Initiated Coverage	Outperform ➝ Outperform	$77.00	High
3/5/2019	Bank of America	Boost Target	Neutral	$59.00 ➝ $65.00	Low
2/27/2019	Oppenheimer	Boost Target	Outperform	$57.00 ➝ $68.00	Medium
2/27/2019	Cowen	Boost Target	Outperform	$40.00 ➝ $60.00	Medium
2/27/2019	Craig Hallum	Boost Target	Buy	$59.00 ➝ $70.00	Medium
2/27/2019	Lake Street Capital	Boost Target	Buy ➝ Buy	$60.00 ➝ $100.00	High
2/27/2019	Piper Jaffray Companies	Upgrade	Overweight	$67.00	High
2/15/2019	Robert W. Baird	Boost Target	Outperform	$46.00 ➝ $55.00	Medium
11/27/2018	UBS Group	Initiated Coverage	Neutral	$36.00	High
11/21/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$46.00	High
11/9/2018	Oppenheimer	Set Target	Buy	$57.00	Medium
11/3/2018	Lake Street Capital	Set Target	Buy	$60.00	High
11/2/2018	Craig Hallum	Set Target	Buy	$59.00	High
11/2/2018	Oppenheimer	Set Target	Buy	$57.00	High
10/15/2018	Lake Street Capital	Set Target	Buy	$60.00	High
9/26/2018	Dougherty & Co	Boost Target	Buy	$45.00 ➝ $56.00	Low
9/26/2018	Piper Jaffray Companies	Reiterated Rating	Above Average ➝ Overweight	$32.00 ➝ $56.00	Medium
9/25/2018	Oppenheimer	Reiterated Rating	Buy	$57.00	Low
9/20/2018	Craig Hallum	Initiated Coverage	Buy	$52.00 ➝ $52.00	Low
9/14/2018	Robert W. Baird	Downgrade	Outperform ➝ Neutral		Medium
9/5/2018	Oppenheimer	Set Target	Buy	$54.00	High
8/30/2018	Berenberg Bank	Initiated Coverage	Buy ➝ Buy	$50.00	High
8/24/2018	Dougherty & Co	Initiated Coverage	Buy ➝ Buy	$45.00	High
8/24/2018	Bank of America	Upgrade	Underperform ➝ Neutral	$45.00	High
8/22/2018	Stifel Nicolaus	Initiated Coverage	Hold	$25.00 ➝ $34.00	High
8/20/2018	Lake Street Capital	Boost Target	Buy	$35.00 ➝ $65.00	Low
8/6/2018	Oppenheimer	Set Target	Buy	$31.00 ➝ $38.00	High
7/31/2018	Oppenheimer	Set Target	Buy	$31.00	High
7/31/2018	Lake Street Capital	Boost Target	Buy	$35.00	High
7/31/2018	Piper Jaffray Companies	Boost Target	Overweight	$32.00	High
7/31/2018	Stifel Nicolaus	Reiterated Rating	Hold ➝ Hold	$7.50 ➝ $25.00	High
7/31/2018	Cowen	Reiterated Rating	Buy	$28.00	High
7/23/2018	Robert W. Baird	Reiterated Rating	Buy	$31.00	High
6/22/2018	Piper Jaffray Companies	Upgrade	Overweight	$25.00	High
6/18/2018	Lake Street Capital	Initiated Coverage	Buy	$30.00	High
5/27/2018	Oppenheimer	Set Target	Buy	$15.00	High
5/21/2018	Oppenheimer	Set Target	Buy	$10.00 ➝ $15.00	High
5/14/2018	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight		High
4/6/2018	Oppenheimer	Set Target	Buy	$8.00	High
3/28/2018	Cowen	Upgrade	Market Perform ➝ Outperform		Medium
3/23/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform		High
3/22/2018	Oppenheimer	Reiterated Rating	Buy		Medium
3/2/2018	Stifel Nicolaus	Reiterated Rating	Hold	$4.00	High
2/27/2018	Cowen	Reiterated Rating	Hold		Medium
2/27/2018	Citigroup	Initiated Coverage	Outperform	$5.50	Low
2/26/2018	Oppenheimer	Initiated Coverage	Buy	$5.50 ➝ $6.00	High

(Data available from 2/7/2018 forward)

News Sentiment Rating

1.46 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

8 very positive mentions
1 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/12/2022

8 very positive mentions
5 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

8/11/2022

5 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/10/2022

7 very positive mentions
0 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/10/2022

13 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/9/2022

6 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/9/2022

10 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/8/2023

15 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/7/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

markets.businessinsider.com
1/11/2023
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Exact Sciences (EXAS)
msn.com
1/10/2023
Tandem Diabetes stock rises after preliminary sales hit reduced guidance, 2023 forecast exceeds mark
markets.businessinsider.com
1/10/2023
Tandem Diabetes Care Reports Q4 Preliminary Sales

Very Positive

marketbeat.com
7 hours ago
New York State Common Retirement Fund Buys 47,133 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
americanbankingnews.com
2/6/2023
Analysts Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target at $72.08
marketbeat.com
2/3/2023
Yousif Capital Management LLC Sells 2,999 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com
2/1/2023
Eagle Asset Management Inc. Purchases Shares of 520,778 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com
1/31/2023
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Today's Range

Now: $43.93

$42.65

$44.15

50 Day Range

MA: $42.41

$39.36

$46.50

52 Week Range

Now: $43.93

$33.51

$124.03

Volume

173,885 shs

Average Volume

949,803 shs

Market Capitalization

$2.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?: The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Cowen Inc, Cowen Inc., Craig Hallum, Jefferies Financial Group Inc., Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, SVB Leerink LLC, TheStreet, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for TNDM.
What is the current price target for Tandem Diabetes Care?: 14 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $75.50, suggesting a possible upside of 74.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting TNDM will reach $130.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $43.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.
What is the current consensus analyst rating for Tandem Diabetes Care?: Tandem Diabetes Care currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.
What other companies compete with Tandem Diabetes Care?: Other companies that are similar to Tandem Diabetes Care include NuVasive, Glaukos, Axonics, Inari Medical and iRhythm Technologies. Learn More about companies similar to Tandem Diabetes Care.
How do I contact Tandem Diabetes Care's investor relations team?: Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is (858) 366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is www.tandemdiabetes.com. Learn More about contacing Tandem Diabetes Care investor relations.

Tandem Diabetes Care - TNDM Stock Price Target and Predictions

Analyst Price Target for TNDM

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.46 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

What is the current price target for Tandem Diabetes Care?

What is the current consensus analyst rating for Tandem Diabetes Care?

What other companies compete with Tandem Diabetes Care?

How do I contact Tandem Diabetes Care's investor relations team?